Loading…
Loading…
Structure Therapeutics Inc. Sponsored ADR (NASDAQ: GPCR - Get Free Report) has earned a consensus rating of "Moderate Buy" from the sixteen ratings firms that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating, twelve have issued a buy rating and
SAN FRANCISCO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on chronic weight management, today announced multiple upcoming poster presentations at The Obesity Society's Annual Meeting, ObesityWeek®, taking place from November 14–17, 2026 in National Harbor, MD. Title: Aleniglipron in Participants Living with Overweight or Obesity: ACCESS Trial Open-Label Extension Date/Time: November 15, 2026, 2:30 p.m.
Structure Therapeutics Inc. Sponsored ADR (NASDAQ: GPCR - Get Free Report) hit a new 52-week low during mid-day trading on Wednesday. The company traded as low as $22.10 and last traded at $22.31, with a volume of 1,434,790 shares changing hands. The stock had previously closed at $23.91. Wall Street Analyst Weigh In Several analysts recently
NVO's 11% slide in a month reflects intensifying LLY competition, pricing pressure and a lack of near-term growth visibility despite its long-term pipeline potential.
Shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ: GPCR - Get Free Report) have received an average recommendation of "Moderate Buy" from the seventeen research firms that are presently covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, one has issued a hold recommendation, twelve have issued a
LLY's GLP-1 momentum, Foundayo launch and retatrutide pipeline support growth, but premium valuation and rising competition weigh on the stock.
Structure Therapeutics Inc. (GPCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Structure Therapeutics remains a Strong Buy, with recent data de-risking its lead oral obesity drug, aleniglipron. Aleniglipron's 72-week open-label data showed 16.2% weight loss, low AE discontinuations, and no DILI, though Phase 3 efficacy and safety monitoring remain key. ACCG-2671, an oral amylin agonist, now has human data and offers potential for combination therapy, further differentiating GPCR's pipeline.